



James C. Dickerson, MD MS

Instructor, Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

- **Stanford Womens Cancer Center**

900 Blake Wilbur

MC 5348

Palo Alto, CA 94304

Tel (650) 498-6004

Fax (650) 490-7237

Bio

BIO

Dr. Dickerson is a medical oncologist in the Division of Medical Oncology at Stanford University School of Medicine, specializing in treating patients with breast cancer. His research studies how health policy can improve health equity and eliminate cancer disparities. To achieve this goal, his research group pursues three key objectives: (1) developing financially sustainable breast cancer care programs, (2) analyzing large databases to identify health policies that can improve equity, and (3) conducting clinical research to discover the most effective ways to deliver high-quality care.

Dr. Dickerson's research has a domestic and an international arm. His global oncology research leverages long-standing collaborations in Nigeria and Belize. Both arms focus on the same objectives of achieving financially sustainable and equitable cancer care.

Dr. Dickerson received his undergraduate degree from Vanderbilt University and graduated magna cum laude from the University of Mississippi Medical Center. He completed his internship and residency in Internal Medicine at Stanford University, followed by fellowship training in Hematology/Oncology at Stanford. During his fellowship, Dr. Dickerson earned a Master's in Health Policy and did post-doctoral research in the Department of Health Policy.

CLINICAL FOCUS

- Breast Cancer
- Oncology

ACADEMIC APPOINTMENTS

- Instructor, Medicine - Oncology

HONORS AND AWARDS

- Conquer Cancer Merit Award, American Society for Clinical Oncology (2024)
- AOA, Alpha Omega Alpha (2018)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Global Health Faculty#Fellow, Center for Innovation in Global Health (CIGH) (2024 - present)
- Member, American Society of Clinical Oncology (ASCO) (2021 - present)

PROFESSIONAL EDUCATION

- Fellowship, Stanford University , Hematology and Oncology (2024)
- MS, Stanford University , Health Policy (2024)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2021)
- Residency, Stanford University , Internal Medicine (2021)
- MD, University of Mississippi Medical Center (2018)
- BA, Vanderbilt University (2014)

Publications

PUBLICATIONS

- **Use of surgery for de novo metastatic breast cancer (mBC)**
Dickerson, J., Tang, H., Thompson, C., Gomez, S. L., Satoyoshi, M., Kurian, A. W., Caswell-Jin, J.
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Real-world duration of interruptions in imaging and endocrine therapy (ET) after pregnancy in early-stage estrogen receptor (ER) positive breast cancer (BC)**
Lewinsohn, R. M., Dickerson, J., Ransohoff, J., Luo, I., Satoyoshi, M., Ritter, V., Schapira, L., Kurian, A. W.
LIPPINCOTT WILLIAMS & WILKINS.2024
- **Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan** *CURRENT PROBLEMS IN CANCER: CASE REPORTS*
Testa, S., Dickerson, J. C., Telli, M.
2023; 11
- **Patient expectations and understanding of treatment intent in Belize.**
Dickerson, J., Wong, W., Ohanian, A., Habet, M., Bernard, M., Huang, F. W., Yacab, R.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Time From Symptom Development to Care Milestones at the Only Public Oncology Clinic in Belize**
Wong, W., Dickerson, J., Habet, M., Bernard, M., Kelly, L., Lattin, J., Garrity, P., Huang, F., Yacab, R.
AMER ASSOC CANCER RESEARCH.2023
- **Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer**
Dickerson, J., Moen, M., Nielsen, P., Tran, E., Suen, W., Goldhaber-Fiebert, J. D., Alarid-Escudero, F.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **The financial toxicity of chemotherapy in Belize**
Wong, W., Dickerson, J., Lattin, J., Ohanian, A., Habet, M., Bernard, M., Huang, F. W., Yacab, R.
LIPPINCOTT WILLIAMS & WILKINS.2023
- **Cancer Demographics and Time-to-Care in Belize.** *The oncologist*
Wong, W., Dickerson, J. C., Valtis, Y. K., Habet, M., Bernard, M., Kelly, L., Lattin, J., Garrity, P., Sood, R., Ohanian, A., Chege, M. W., Bhatt, A. S., Huang, et al
2023
- **Implementation and efficacy of a fellow-led, case-based noon lecture series.**
Dickerson, J., Myall, N., Roy, M., Johnson, T.
LIPPINCOTT WILLIAMS & WILKINS.2022
- **Breast cancer characteristics and time to chemotherapy initiation in Belize.**

-
- Wong, W., Dickerson, J., Sood, R., Yacab, R., Valtis, Y., Lattin, J., Garrity, P., Bhatt, A., Huang, F. W.
LIPPINCOTT WILLIAMS & WILKINS.2022: E18643
- **Updated demographics at the only public oncology clinic in Belize.**
Wong, W., Dickerson, J., Sood, R., Valtis, Y., Yacab, R., Lattin, J., Garrity, P., Bhatt, A., Huang, F. W.
LIPPINCOTT WILLIAMS & WILKINS.2022: E18787
 - **Patient-reported outcome measurement implementation in cancer survivors: a systematic review.** *Journal of cancer survivorship : research and practice*
Singhal, S., Dickerson, J., Glover, M. J., Roy, M., Chiu, M., Ellis-Caleo, T., Hui, G., Tamayo, C., Loecher, N., Wong, H. N., Heathcote, L. C., Schapira, L.
2022
 - **Implementing Patient-Directed Cancer Education Materials Across Nigeria.** *JCO global oncology*
Dickerson, J. C., Ibeka, P., Inoyo, I., Oke, O. O., Adewuyi, S. A., Barry, D., Bello, A., Fasawe, O., Garrity, P., Habeebu, M., Huang, F. W., Mulema, V., Nwankwo, et al
2021; 7: 1610-1619
 - **Financial Toxicity of Cancer Care: An Analysis of Financial Burden in Three Distinct Health Care Systems.** *JCO oncology practice*
Parikh, D. A., Ragavan, M., Dutta, R., Garnet Edwards, J., Dickerson, J., Maitra, D., Aggarwal, S., Lee, F., Patel, M. I.
2021: OP2000890
 - **Healthcare delivery interventions to reduce cancer disparities worldwide.** *World journal of clinical oncology*
Dickerson, J. C., Ragavan, M. V., Parikh, D. A., Patel, M. I.
2020; 11 (9): 705–22
 - **Health Disparities in Germline Genetic Testing for Cancer Susceptibility** *Current Breast Cancer Reports*
Parikh, D. A., Dickerson, J. C., Kurian, A. W.
2020
 - **Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review** *JOURNAL OF PAIN AND SYMPTOM MANAGEMENT*
Hall, E. T., Singhal, S., Dickerson, J., Gabster, B., Wong, H., Aslakson, R. A., Schapira, L., Ast, K., Carroll, T., Dzung, E., Harrison, K. L., Kaye, E. C., LeBlanc, et al
2019; 58 (1): 137-+
 - **Variations in patient-reported outcome (PRO) collection and reporting in novel FDA approved anticancer therapies.**
Singhal, S., Hall, E., Gabster, B., Dickerson, J., Schapira, L.
AMER SOC CLINICAL ONCOLOGY.2019
 - **"If you don't ask, you won't know": Do patient reported outcome (PRO) instruments capture the symptom experience of patients treated with immune checkpoint inhibitors (ICIs)?**
Gabster, B., Hall, E., Singhal, S., Dickerson, J., Schapira, L.
AMER SOC CLINICAL ONCOLOGY.2019
 - **The impact of blinding on patient-reported outcomes (PROs) in randomized controlled trials of immune checkpoint inhibitors versus traditional chemotherapies.**
Dickerson, J., Hall, E., Singhal, S., Gabster, B., Schapira, L.
AMER SOC CLINICAL ONCOLOGY.2019
 - **Patient reported outcomes for cancer patients receiving immunotherapy: opportunities for palliative care - A Systematic Review.** *Journal of pain and symptom management*
Hall, E. T., Singhal, S., Dickerson, J., Gabster, B., Wong, H., Aslakson, R. A., Schapira, L.
2019
 - **Screening duplex ultrasonography in neurosurgery patients does not correlate with a reduction in pulmonary embolism rate or decreased mortality.** *Journal of neurosurgery*
Dickerson, J. C., Harriel, K. L., Dambrino, R. J., Taylor, L. I., Rimes, J. A., Chapman, R. W., Desrosiers, A. S., Tullis, J. E., Washington, C. W.
2019: 1–9